



NUMERAL LTD

(formerly Go Life International Ltd)

(Incorporated in the Republic of Mauritius)

(Registration number: 098177 C1/GBL)

Primary Listing SEM share code: GOLI.N0000

Secondary Listing JSE share code: XII

ISIN: MU0330N00004

("the Company" or "Numeral")

UNAUDITED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 31 MAY 2025 ("Q1") AND CHANGE IN DIRECTOR

DIRECTORS' COMMENTARY

BACKGROUND

The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Global Business Licence issued by the Mauritius Financial Services Commission.

Numeral is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius ("SEM") on 7 July 2011. The Company completed a secondary listing on the Alternative Exchange ("AltX") of the Johannesburg Stock Exchange Limited ("the JSE") on 23 November 2016.

During the prior year, the Company recovered its 50% interest in Cryo-Save South Africa Proprietary Limited ("Cryo-Save"), as detailed in the Company's original announcement dated 18 December 2020 wherein the Company (formerly known as Go Life) advised that it had added Cryo-Save to its group of companies. The recovery of the interest was for no consideration. The Company had effective control over the Cryo-Save operations from 1 September 2024 and thus the comparative numbers for Q1 do not include any numbers relating to Cryo-Save.

It is also noted that this is the first quarter in a number of years that the Company is reporting as a group and the prior year's numbers will not be strictly comparable.

The main focus of the Group remains on biotechnology, health and pharmaceuticals.

ACQUISITIONS AND DISPOSALS

The following acquisitions and organic growth have been implemented during the financial period of the company and as post balance sheet events:

- Numeral acquired an additional 1% interest in Cryo-Save on 1 March 2025. This takes Numeral to 51% shareholding in Cryo-Save.
- Numeral acquired an effective 51% shareholding in Longevity Lab Proprietary Limited ("Longevity") with effect from 1 March 2025 through an issue of ordinary shares in Longevity for cash.
- Numeral acquired an effective 40% shareholding in Isopharm Proprietary Limited ("Isopharm") with effect from 15 May 2025 through an issue of ordinary shares in Isopharm for cash.
- Numeral established a new entity named Celerevive Proprietary Limited ("Celerevive") during the 2025 financial year of which it sold 49% to the Celerevive management team on 1 March 2025. Operations commenced in May 2025.

- Numeral has undertaken a consolidation of its SA operating entities under a central SA holding company, named Numeral SA Holdings Proprietary Limited ("NSH"), established on 18 March 2025, which will be effective in the 2026 financial year.
- Numeral established Numeral Treasury Solutions Limited on 19 April 2025, to house the Domestic Medium-Term Note ("DMTN") program in preparation for its debt listing on the Johannesburg Stock Exchange, which will take place in the 2026 financial year.
- Numeral established Qantara Private Capital Proprietary Limited ("Qantara") as a 100% held subsidiary of Numeral Financial Services Proprietary Limited ("NFS") on 8 April 2025. Qantara established three Shariah compliant, ethically aligned private equity funds namely: the Qantara Income Fund, the Qantara Growth Fund and the Qantara Property Fund, each as *en commandite* partnerships.
- Numeral established Numeral DRC Holdings ("NDRCH") in preparation for its future expansion of operations into the Democratic Republic of Congo. Our intention is to only activate operations in this entity in the second half of the 2026 financial year.

There were no further acquisitions or disposals during the period under review.

RELATED PARTIES

There were no transactions with related parties during the period under review that are material to these results.

BASIS OF PREPARATION

These results have been prepared in accordance with International Financial Reporting Standards (IFRS), the SEM Listings Rules and the JSE Listings Requirements. The accounting policies adopted in the preparation of these Q1 results are in terms of IFRS and are consistent with those applied in the preparation of the audited financial statements for the year ended 28 February 2025.

These results have been prepared under the supervision of Mr JD Botma.

SEGMENTAL ANALYSIS

There are no separate segments on which to report with all operations currently being conducted in South Africa.

EVENTS AFTER THE REPORTING PERIOD

There were no material subsequent events after 31 May 2025.

PROSPECTS

Numeral is dedicated to regrowing its healthcare and biotech business as well as embracing technological and commercial opportunities in the biotech and pharmaceutical vertical. It will also seek to diversify the Group through strategic acquisitions and pursuing new distribution channels through innovative platforms and strategic partnerships.

At the stage when a strategic acquisition is undertaken, in meeting the requirements, the Company will issue a listing circular, incorporating revised listing particulars, in accordance with the SEM Listings Rules and the JSE Listings Requirements. The information regarding the prospects of the Company included in this paragraph, including any forward-looking information, were not audited or reviewed by the Company's auditors.

GOING CONCERN

The Group has started to show profits, is generating cash and retains the ongoing support of key shareholders.

DIVIDENDS

No dividends were authorised or paid during the period under review.

CHANGE IN DIRECTOR

Mr. Glenn Henning was appointed to the Board as a Non-Executive Director with effect from 13 March 2025 and served until 15 July 2025.

The Board of Directors of Numeral Limited ("the Company") wishes to inform shareholders that Mr. Glenn Henning has tendered his resignation as a director of the Company.

Mr. Henning's resignation forms part of a strategic decision to focus his efforts on driving the growth and operational scaling of key subsidiaries within the Numeral Group. This transition aligns with the Group's broader restructuring and renewed focus on execution at the subsidiary level.

The Board extends its sincere appreciation to Mr. Henning for his significant contributions to Numeral Limited and looks forward to his continued leadership within the Group's portfolio companies.

QUARTERLY INFORMATION

The Company is required to publish quarterly financial results for the three months ended 31 May 2025 in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited quarterly financial statements ("QFS") have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards ("IFRS") and the SEM Listing Rules and the JSE Listings Requirements.

STATEMENT OF PROFIT AND OTHER COMPREHENSIVE INCOME – UNAUDITED QUARTERLY INFORMATION

USD	Unaudited May 2025	Audited Feb 2025	Unaudited May 2024
Revenue	542 779	1 692 555	9 995
Expenses	(101 252)	(368 466)	8 327
Operating Income from Operations	441 527	1 324 089	1 668
Administrative expenses	(16 612)	(47 874)	
Other expenses	(348 682)	(804 248)	
Foreign exchange loss	3 087	(221 932)	
Net Income Before Taxation	79 320	250 035	1 668
Taxation	(3 598)	(68 101)	-
Net Profit After Taxation	75 722	181 934	1 668
Other Comprehensive Income	-	-	-
Total Comprehensive Income for the Period	75 722	181 934	1 668
Net profit attributed to:	75 722	181 934	1 668
Owners of the parent	53 465	168 786	1 668
Non-controlling interests	22 257	13 148	-
Total comprehensive income attributed to:	75 722	181 934	1 668
Owners of the parent	53 465	168 786	1 668
Non-controlling interests	22 257	13 148	-
Earnings per share based on weighted average shares	0.004	0.014	0.00013

STATEMENT OF FINANCIAL POSITION – UNAUDITED QUARTERLY INFORMATION

USD	Unaudited May 2025	Audited Feb 2025	Unaudited May 2024
ASSETS			
Non-current Assets	1 793 508	1 121 816	-
Deferred tax	358 214	346 460	-
Loan receivables	1 284 725	641 700	-
Property, Plant and Machinery	131 173	133 656	-
Investment in associates	19 396		
Current Assets	1 369 275	1 665 178	42 298
Trade and other receivables	1 067 335	895 482	41 955
Cash and Cash Equivalents	136 223	212 662	303
Inventory	45 630	32 689	-
Loan receivables	120 087	524 345	-
TOTAL ASSETS	3 162 783	2 786 994	42 298
EQUITY			
Capital and Reserves	(1 894 098)	(1 992 079)	(145 297)
Share Capital	7 926 898	7 926 898	28 460 357
Accumulated Loss	(27 897 205)	(27 972 928)	(28 605 654)
Share premium	20 533 459	20 533 459	-
Other reserves	(1 443 782)	(1 443 782)	-
Non-controlling interest	(1 013 468)	(1 035 725)	-
LIABILITIES			
Non-Current Liabilities	4 480 892	4 025 833	-
Deferred income	-	225 625	-
Borrowings	4 480 892	3 800 208	-
Current Liabilities	575 989	753 240	187 595
Loans from shareholders	-	-	91 033
Trade and other Payables	547 369	554 771	69 712
Amounts due to other related parties	-	-	26 849
Deferred income	25 022	19 908	-
Borrowings	-	171 031	-
Income tax liabilities	3 598	7 530	-
TOTAL EQUITY AND LIABILITIES	3 162 783	2 786 994	42 298

STATEMENT OF CASH FLOWS – UNAUDITED QUARTERLY INFORMATION

USD	Unaudited May 2025	Audited Feb 2025	Unaudited May 2024
Cash flows from operating activities	661 649	(2 076 565)	(14 225)
Cash used in operations	-	-	(14 225)
Profit for the year	79 320	250 035	-
<i>Adjustment for:</i>			
Depreciation for property, plant and equipment	1 163	382 311	-
Consolidation adjustments	773 362	(2 145 370)	-
<i>Changes in working capital</i>			
Inventory	(12 941)	(32 689)	-
Other receivables	(171 853)	(895 482)	-
Other payables	(7 402)	364 327	-
Cash flows from financing activities	(527 909)	2 805 194	14 225
Repayments of loans from group companies	(238 767)	(1 166 045)	13 225
Repayments of financial liabilities at fair value	-	-	1 000
Proceeds from borrowings	(289 142)	3 971 239	-
Cash flows (used in)/generated from investing activities	2 483	(515 967)	-
Acquisition of property, plant and machinery	2 483	(515 967)	-
Net cash flow for period under review	(76 439)	212 359	-
Cash and cash equivalents at the beginning of the year	212 662	303	303
Cash and cash equivalents at the end of the year	136 223	212 662	303

STATEMENT OF CHANGES IN EQUITY

Figures in US Dollars	Share capital	Share premium	Accumulated loss	Consolidated reserves	Attributed to equity holders of Group	Non- controlling interest	Total equity
Balance at 01 March 2024	7 926 898	20 533 459	(28 141 714)	-	318 644	(1 048 873)	(730 229)
Profit for the year	-	-	168 786	-	168 786	13 148	181 934
Other reserves arising on consolidation	-	-	-	(1 443 782)	(1 443 782)	-	(1 443 782)
Other comprehensive income	-	-	-	-	-	-	-
Balance at 28 February 2025	7 926 898	20 533 459	(27 972 928)	(1 443 782)	(956 352)	(1 035 725)	(1 992 077)
Profits for the quarter ended 31 May 2025	-	-	53 465	-	53 465	22 257	75 722
Balance at 31 May 2025	7 926 898	20 533 459	(27 919 463)	(1 443 782)	(902 887)	(1 013 468)	(1 916 355)

RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS

USD	Unaudited 3 months 31 May 2025	Audited Feb 2025	Unaudited 3 months 31 May 2024
Basic earnings per share attributable to Parent	53 465	168 786	1 668
Adjustments to headline earnings:	-	-	-
Headline earnings per share	53 465	168 786	1 668
Weighted average number of shares (net of treasury shares)	1 242 500 000	1 242 500 000	1 242 500 000
Basic and diluted loss per share (USD cents)	0.004	0.014	0.00013
Headline loss per share (USD cents)	0.004	0.014	0.00013

AVAILABLE INFORMATION

Copies of the audited Annual Financial Statements for the year ended 28 February 2025 and the abridged unaudited quarterly financial statements for the three months ended 31 May 2025 and the statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the at the registered office of the Company at Unit 13 Socota Phoenicia, Sayed Hossen Road, Phoenix Mauritius.

This communiqué is issued pursuant to SEM Listing Rules 11.3, 12.14 and 12.20 and section 88 of the Securities Act of Mauritius 2005 as well as the JSE Listings Requirements. The Board accepts full responsibility for the accuracy of the information contained in these abridged results. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 31 May 2025 that require any additional disclosure or adjustment to the Financial Statements.

Numeral has its primary listing on SEM and a secondary listing on the AltX of the JSE.

For and on behalf of the board

Mauritius

16 July 2025

Executive Directors:

Dave van Niekerk
Neville Graham

Non-Executive Directors:

Mohamed Yusuf Sooklall (MSK)
Dr Aansa Devi Bedacee

JSE Sponsor:

AcaciaCap Advisors Proprietary Limited

Management Company and Company Secretary:

LTS Management Services Limited
